Deals


  • Pfizer, Roivant set up new company around inflammation drug

    The drug is currently in mid-stage testing as a treatment for ulcerative colitis. If it continues to advance, it could be the first approved therapy aimed at a protein known as TL1A, a target multiple other companies are pursuing. 

    By Dec. 1, 2022
  • Image attribution tooltip
    Brian Tucker / BioPharma Dive

    Large pharmas probe takeover of Horizon Therapeutics

    The Dublin-headquartered drugmaker confirmed it is in "highly preliminary" talks with Amgen, J&J and Sanofi, although it cautioned no offer may ever materialize.

    By Updated Nov. 30, 2022
  • Explore the Trendline
    Image attribution tooltip
    Brian Tucker / BioPharma Dive
    Trendline

    Biotech dealmaking

    Acquisitions of biotech companies have picked up in recent quarters, suggesting depressed valuations may be facilitating deal conversations. Read this trendline for a look at the factors impacting M&A. 

    By BioPharma Dive staff
  • 3D rendering of T cells attacking a cancer cell.
    Image attribution tooltip
    Meletios Verras via Getty Images

    AstraZeneca reveals its cell therapy ambitions with deal for startup

    The British drugmaker will pay as much as $320 million to acquire Neogene Therapeutics, a developer of cell-based treatments for solid tumors — its first significant investment in the field.

    By Nov. 29, 2022
  • A wall showing a Merck & Co. logo in Kenilworth, New Jersey
    Image attribution tooltip
    Courtesy of Merck & Co.

    Merck to buy blood cancer biotech Imago for $1.35B

    The deal is Merck’s second notable acquisition in the past year and a half, part of a strategy to diversify its pipeline beyond the top-selling Keytruda.

    By Nov. 21, 2022
  • A photo of Regeneron's Tarrytown, NY headquarters.
    Image attribution tooltip
    Regeneron

    Regeneron teams up with CytomX to develop dual-targeting cancer drugs

    Regeneron will pay CytomX $30 million to try to create bispecific antibody drugs that are safer and have a wider reach than existing treatments.  

    By Nov. 17, 2022
  • Portrait of Joanne Kotz and Joel Barrish, two of Jnana Therapeutics' co-founders.
    Image attribution tooltip
    Permission granted by Jnana Therapeutics

    Jnana deepens ties with Roche and grabs a new round of funding

    The startup, developing drugs that target an untapped class of proteins called solute carriers, has now formed two lucrative alliances with the Swiss drugmaker since 2020.

    By Nov. 15, 2022
  • An illustration of dollar signs and small pills coming together to make one larger pill, representing a biopharma deal.
    Image attribution tooltip
    Brian Tucker / BioPharma Dive

    Narcan developer to be acquired by Indivior

    The deal, which could carry a total value of roughly $145 million, is in large part focused on a nasal formulation of the opioid overdose drug nalmefene.

    By Nov. 14, 2022
  • Two test tubes pour different-colored liquids into a beaker in an illustration representative of biopharma mergers.
    Image attribution tooltip
    Elizabeth Regan / Industry Dive

    Centerview grows role as go-to adviser for biopharma dealmaking

    Over the past several years, the investment advisory firm has served as a financial adviser on biopharma acquisitions worth more than $200 billion in total, with the latest announced Monday.

    By Nov. 8, 2022
  • A corporate building is seen with a sign for the company Viatris
    Image attribution tooltip
    Courtesy of Viatris

    Viatris to buy two eye drug developers in deals worth up to $750M

    The generics company is acquiring Oyster Point Pharma and the privately held Famy Life Sciences in a move aimed at creating an ophthalmology business.

    By Updated Nov. 7, 2022
  • Colorized scanning electron micrograph of a natural killer cell from a human donor.
    Image attribution tooltip
    National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.

    Artiva cancels IPO plans and cuts a deal with Affimed

    With public offerings difficult to pull off, Artiva is focusing its energy on developing a cancer drug with the German biotech.

    By Nov. 3, 2022
  • Image attribution tooltip
    Mario Tama via Getty Images

    J&J to buy heart device maker Abiomed for $16.6B

    The deal is the biggest by J&J since its $30 billion buyout of Actelion in 2017, and comes as the company works to split its consumer health business from its pharma and medtech units. 

    By Elise Reuter • Nov. 1, 2022
  • A rendering of Astellas' planned biotech campus in South San Francisco
    Image attribution tooltip
    Courtesy of Astellas

    Astellas takes stake in gene therapy developer Taysha

    Already an investor in gene therapy, the Japanese pharma will buy 15% of the Texas biotech’s stock and gain options to two gene therapies for central nervous system disorders.

    By Oct. 24, 2022
  • Two test tubes pour different-colored liquids into a beaker in an illustration representative of biopharma mergers.
    Image attribution tooltip
    Elizabeth Regan / Industry Dive

    Myovant agrees to sell after buyer ups price

    Sumitomo Pharma, a Japanese drug company that already owns 52% of Myovant, is now offering to buy all the remaining shares for $27 apiece in a deal that values the biotech at $2.9 billion.

    By Oct. 24, 2022
  • A photo of a declining stock price.
    Image attribution tooltip
    Leonid Sorokin via Getty Images

    AGTC yields to biotech downturn with gene therapy buyout deal

    The biotech is the latest in a growing list of genetic medicine developers to sell themselves near record stock lows amid a challenging funding environment.  

    By Oct. 24, 2022
  • The outside of an AbbVie building, with the company's logo displayed.
    Image attribution tooltip
    AbbVie

    AbbVie to buy UK biotech DJS for $255M

    The deal gives AbbVie an experimental medicine for idiopathic pulmonary fibrosis, as well as a platform for designing antibody drugs that can target proteins known as GPCRs.

    By Oct. 20, 2022
  • Image attribution tooltip
    Mario Tama via Getty Images

    J&J, flush with cash, says high valuations remain a dealmaking hurdle

    “We don’t have to do anything out of desperation,” said CFO Joseph Wolk on J&J’s second quarter earnings call. J&J holds $34 billion in cash and other liquid assets. 

    By Oct. 18, 2022
  • A photo of renal cell carcinoma.
    Image attribution tooltip
    OGphoto via Getty Images

    Aveo sells to LG Chem after turnaround for kidney cancer drug

    The biotech survived multiple drug rejections, shareholder lawsuits and a federal investigation before winning approval of Fotivda, the centerpiece of its $566 million buyout on Tuesday.

    By Oct. 18, 2022
  • Lilly bets more than $600M on a gene therapy developer targeting hearing loss

    Like with Prevail Therapeutics, Lilly’s first gene therapy acquisition, the pharma’s planned buyout of Akouos includes a contingent value right that could hike the deal’s overall cost.

    By Oct. 18, 2022
  • People walk past the Nasdaq MarketSite on October 12, 2022 in New York City.
    Image attribution tooltip
    Michael M. Santiago via Getty Images

    Enliven to enter public markets through reverse merger with Imara

    With the IPO market still depleted, Enliven, a precision oncology company, has found a different path to the Nasdaq stock exchange.

    By Oct. 14, 2022
  • PureTech, Nektar end talks of combination

    Days after acknowledging that discussions were taking place, the two companies have called off further negotiations over a possible deal, leaving Nektar’s future again uncertain.

    By Updated Oct. 11, 2022
  • A researcher, wearing a navy blue lab coat with the Incyte logo above a breast pocket, works in a research lab.
    Image attribution tooltip
    Permission granted by Incyte

    Incyte, branching out in dermatology, to buy startup Villaris

    The acquisition, Incyte’s first of an entire company, hands the pharmaceutical company a potentially long lasting treatment for the skin disease vitiligo.

    By Oct. 3, 2022
  • Pedestrians walk beside a stone wall with gilded letters spelling out "14 Wall Street."
    Image attribution tooltip
    Spencer Platt via Getty Images

    Myovant rejects $2.4B buyout offer from Japanese majority owner

    The biotech said the proposed offer “significantly undervalues” the company, but that it’s open to considering a higher bid.

    By Oct. 3, 2022
  • A general view of AstraZeneca is seen during Prime Minister Scott Morrison's visit on August 19, 2020 in Sydney, Australia.
    Image attribution tooltip
    Lisa Maree Williams via Getty Images
    Gene editing

    AstraZeneca to acquire gene editing biotech LogicBio

    Shares in LogicBio had lost nearly all their value since a 2018 IPO, bringing the company to the brink of Nasdaq delisting. The buyout deal represents a premium of over 600%.

    By Oct. 3, 2022
  • An illustration of an adeno-associated virus.
    Image attribution tooltip
    Dr_Microbe via Getty Images
    Emerging biotech

    Solid Bio yields to Sarepta on Duchenne with plans for merger, R&D shakeup

    The biotech, which fell behind Sarepta in developing a Duchenne gene therapy, will merge with AavantiBio, a startup run by a former Sarepta executive.

    By Sept. 30, 2022
  • A brown and gray-haired man smiles at the camera.
    Image attribution tooltip
    Permission granted by Ventus Therapeutics

    Ventus sells its lead drug candidate to Novo Nordisk

    The biotech will part with its lead drug candidate, an anti-inflammatory small molecule, in Novo Nordisk’s bet on inflammasome treatments.

    By Sept. 29, 2022